ArticleFrontiers in oncology2023

TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial.

Weili Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.